Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Chronic Lymphocytic Leukemia clinical trials

Directory of U.S. ClinicalTrials.gov public records for Chronic Lymphocytic Leukemia. Browse Chronic Lymphocytic Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced July 23, 2026 Report an issue

ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
12
Shown on this page
12
Current sort
Recently updated
Condition scope
Chronic Lymphocytic Leukemia
Additional filters apply within this condition.
The trial list below is retrieved from the live ClinicalTrials.gov search API for Chronic Lymphocytic Leukemia. Results on this page are currently sorted by Recently updated.

How Chronic Lymphocytic Leukemia studies are organized in the registry

CLL is registered together with small lymphocytic lymphoma (SLL) in many records — they are treated as one disease in study design — so listings often carry both names. Drug-class abbreviations, particularly BTK and BCL-2 inhibitor terms, appear directly in current titles.

Terms that often appear in related listings
SLL BTK inhibitor relapsed CLL venetoclax

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Chronic Lymphocytic Leukemia. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Recognized from query: venetoclax. Matching terms were moved into the structured fields above when recognized.
Showing 13–24 of 12 matching trials for Chronic Lymphocytic Leukemia.
Live ClinicalTrials.gov results.
Active filters: "venetoclax" Clear condition filters
Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

NCT04419519
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Not yet recruiting Phase 2 Interventional

Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

NCT07690891
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Nemtabrutinib, Venetoclax, Obinutuzumab
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Sonrotoclax, Obinutuzumab, Rituximab, Venetoclax
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
35
States / cities
Laguna Hills, California • Orange, California • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

NCT04588922
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
SLS009, venetoclax, azacitidine
Drug
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • Goodyear, Arizona • Duarte, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

NCT04623541
View directory record Official record
Conditions
Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Interventions
Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax, Lenalidomide, Pirtobrutinib
Biological · Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • California City, California • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Active, not recruiting Phase 2 Interventional

The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

NCT04447768
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Obinutuzumab, Venetoclax
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Stanford, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

NCT03331198
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Interventions
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
83
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT05091424
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions
Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
5
States / cities
Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Recruiting Phase 2 Interventional

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT05963074
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Venetoclax
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
32
States / cities
Cerritos, California • Los Alamitos, California • San Luis Obispo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT03462719
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Louisville, Kentucky • Hackensack, New Jersey • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

NCT07024706
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Acalabrutinib, Venetoclax
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
4
States / cities
Boston, Massachusetts • Charlotte, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 2:19 PM EDT
Not yet recruiting Phase 2 Interventional

Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT07557056
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Nemtabrutinib, Questionnaire Administration, Venetoclax
Procedure · Drug · Other
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 2:19 PM EDT

About this Chronic Lymphocytic Leukemia clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Chronic Lymphocytic Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Chronic Lymphocytic Leukemia.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Chronic Lymphocytic Leukemia.